Published : Jun-2018
No. of Pages : 146
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 6
2 Introduction 7
2.1 Needle Free Injections Overview 7
3 Products under Development 8
3.1 Needle Free Injections - Pipeline Products by Stage of Development 8
3.2 Needle Free Injections - Pipeline Products by Territory 9
3.3 Needle Free Injections - Pipeline Products by Regulatory Path 10
3.4 Needle Free Injections - Pipeline Products by Estimated Approval Date 11
3.5 Needle Free Injections - Ongoing Clinical Trials 12
4 Needle Free Injections - Pipeline Products under Development by Companies 13
4.1 Needle Free Injections Companies - Pipeline Products by Stage of Development 13
4.2 Needle Free Injections - Pipeline Products by Stage of Development 14
5 Needle Free Injections Companies and Product Overview 15
5.1 B. Braun Melsungen AG Company Overview 15
5.2 Boston Scientific Corp Company Overview 16
5.3 Crossject SA Company Overview 17
5.4 Enable Injections Inc Company Overview 21
5.5 Enesi Pharma Ltd Company Overview 22
5.6 Eternity Healthcare Inc. Company Overview 23
5.7 Inovio Pharmaceuticals Inc Company Overview 24
5.8 Medical International Technologies (Mit Canada) Inc Company Overview 28
5.9 PharmaJet Inc Company Overview 31
5.10 Queen's University Company Overview 36
5.11 Takeda Pharmaceutical Co Ltd Company Overview 37
5.12 Teva Pharmaceutical Industries Ltd Company Overview 38
6 Needle Free Injections- Recent Developments 39
6.1 Jun 08, 2018: B. Braun to Showcase Its Commitment to Reducing Healthcare-Associated Infections with Products and Education at APIC 2018 39
6.2 Jun 06, 2018: Daiichi Sankyo's U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 Percent of Eligible Litigants and Claimants Opt In 40
6.3 May 30, 2018: Antares Pharma Announces Receipt of Third Installment From Sale of ZOMAJET Needle-Free Delivery System 40
6.4 May 21, 2018: Baxter Highlights Business Strategies and Innovation at 2018 Investor Conference 40
6.5 May 11, 2018: Terumo Appoints its U.S.-based Subsidiary's Associate as the Fifth Terumo Fellow 42
6.6 May 11, 2018: Daiichi Sankyo Announces Changes to Representative Directors and Members of the Audit and Supervisory Board 43
6.7 May 09, 2018: ICU Medical Announces First Quarter 2018 Results 43
6.8 May 08, 2018: Antares Pharma Reports First Quarter 2018 Operating and Financial Results 44
6.9 May 03, 2018: Teva Reports First Quarter 2018 Financial Results 45
6.10 May 01, 2018: Merck Announces First-Quarter 2018 Financial Results 51
6.11 Apr 26, 2018: Baxter Reports First-Quarter 2018 Results And Increases Financial Outlook For Full-Year 2018 55
6.12 Apr 26, 2018: Consort Medical: Director Declaration 56
6.13 Apr 25, 2018: Boston Scientific Reports Financial Results For First Quarter 2018 56
6.14 Apr 18, 2018: B. Braun Opens Five New Medical Production Facilities in Penang 58
6.15 Apr 17, 2018: Vaccibody moving forward with Cancer Neoantigen Vaccine Trial 59
6.16 Mar 23, 2018: Aradigm Reports Fourth Quarter 2017 And Full Year Financial Results 60
6.17 Mar 23, 2018: 2017 fiscal year: B. Braun increases sales and earnings, with investments of one billion euros 61
6.18 Mar 20, 2018: Merck Names Jennifer Zachary As General Counsel 63
6.19 Mar 13, 2018: Phase 1 clinical trial for Hantavirus vaccines yields positive interim results 64
6.20 Mar 01, 2018: Antares Pharma Announces Receipt of Second Installment from Sale of Zomajet Needle-Free Delivery System 64
6.21 Mar 01, 2018: ICU Medical Announces Fourth Quarter and Fiscal Year 2017 Results 64
6.22 Feb 28, 2018: Daiichi Sankyo Aligns U.S. Commercial Operations to Current Portfolio and Upcoming Cancer Pipeline 65
6.23 Feb 23, 2018: Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2018 66
6.24 Feb 21, 2018: Daiichi Sankyo Selected for 2018 Certified Health and Productivity Management Organization (White 500) 67
6.25 Feb 13, 2018: Four start-ups chosen for the B. Braun Accelerator Program 67
6.26 Feb 09, 2018: Aradigm Announces Personnel Changes 68
6.27 Feb 08, 2018: Teva Reports 2017 Full Year and Fourth Quarter Financial Results 69
6.28 Feb 08, 2018: Terumo Revises the Full-Year Results Forecast for FY 2017 77
6.29 Feb 06, 2018: Vaccibody Expands Human Clinical Trial of HPV Vaccine 77
6.30 Feb 06, 2018: Teva Pharmaceuticals laid off 46 employees in Parsippany 78
6.31 Feb 02, 2018: Daiichi Sankyo Selected for Silver Class of RobecoSAM Sustainability Award 2018 78
6.32 Feb 01, 2018: Boston Scientific Announces Results for Fourth Quarter and Full Year 2017 78
6.33 Feb 01, 2018: Baxter Reports 2017 Fourth-Quarter and Full-Year Results 80
6.34 Jan 31, 2018: Ferring's ZOMACTON (somatropin) for Injection Receives FDA Approval to Treat Growth Hormone Deficiency in Adults 83
6.35 Jan 25, 2018: Terumo Announces Change of Directors and Executive Officers 83
6.36 Jan 24, 2018: Merck Names Inge Thulin To Board Of Directors 85
6.37 Jan 23, 2018: LENIS Needle-Free Injection System Signs U.S. Exclusive With LenisUSA.com 86
6.38 Jan 23, 2018: Study shows superiority of PharmaJet Needle-free Injector for poliovirus vaccine administration 86
6.39 Jan 19, 2018: Teva Layoffs To Affect 65 Employees In Horsham, North Wales 87
6.40 Jan 18, 2018: B. Braun to Showcase Comprehensive Parenteral Nutrition Program, New Compounder and More at ASPEN 87
6.41 Jan 09, 2018: Zika Virus vaccine shows significantly higher immune response with Needle-free delivery 88
6.42 Jan 09, 2018: Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year Ended December 31, 2017 88
6.43 Jan 09, 2018: Valeritas Appoints Joseph Saldanha as Chief Business Officer 89
7 Appendix 143
7.1 Methodology 143
7.2 About GlobalData 146
7.3 Contact Us 146
7.4 Disclaimer 146
1.1 List of Tables
Table 1: Needle Free Injections - Pipeline Products by Stage of Development 8
Table 2: Needle Free Injections - Pipeline Products by Territory 9
Table 3: Needle Free Injections - Pipeline Products by Regulatory Path 10
Table 4: Needle Free Injections - Pipeline Products by Estimated Approval Date 11
Table 5: Needle Free Injections - Ongoing Clinical Trials 12
Table 6: Needle Free Injections Companies - Pipeline Products by Stage of Development 13
Table 7: Needle Free Injections - Pipeline Products by Stage of Development 14
Table 8: B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview 15
Table 9: Needle-Free System - Product Status 15
Table 10: Needle-Free System - Product Description 15
Table 11: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 16
Table 12: JetTouch System - Overactive Bladder - Product Status 16
Table 13: JetTouch System - Overactive Bladder - Product Description 16
Table 14: Crossject SA Pipeline Products & Ongoing Clinical Trials Overview 17
Table 15: Zeneo ID Human Needle-Free Injection Device - Product Status 17
Table 16: Zeneo ID Human Needle-Free Injection Device - Product Description 18
Table 17: Zeneo IM 0.5ml Needle - Free Injection Device - Product Status 18
Table 18: Zeneo IM 0.5ml Needle - Free Injection Device - Product Description 18
Table 19: Zeneo SC 0.5ml Needle-Free Injection Device - Product Status 19
Table 20: Zeneo SC 0.5ml Needle-Free Injection Device - Product Description 19
Table 21: Zeneo SC 0.8ml Needle-Free Injection Device - Product Status 19
Table 22: Zeneo SC 0.8ml Needle-Free Injection Device - Product Description 20
Table 23: Zeneo SC High Viscosity Needle-Free Injection Device - Product Status 20
Table 24: Zeneo SC High Viscosity Needle-Free Injection Device - Product Description 20
Table 25: Enable Injections Inc Pipeline Products & Ongoing Clinical Trials Overview 21
Table 26: Enable Smart enFuse - Product Status 21
Table 27: Enable Smart enFuse - Product Description 21
Table 28: Enesi Pharma Ltd Pipeline Products & Ongoing Clinical Trials Overview 22
Table 29: Enesi SDI - Product Status 22
Table 30: Enesi SDI - Product Description 22
Table 31: Eternity Healthcare Inc. Pipeline Products & Ongoing Clinical Trials Overview 23
Table 32: Multi Channel Needle-Free Injection Device - Product Status 23
Table 33: Multi Channel Needle-Free Injection Device - Product Description 23
Table 34: Inovio Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 24
Table 35: Iject R Pre-Filled Syringe - Product Status 24
Table 36: Iject R Pre-Filled Syringe - Product Description 24
Table 37: Intradermal Pen Injector - Product Status 25
Table 38: Intradermal Pen Injector - Product Description 25
Table 39: Intradermal Syringe - Product Status 25
Table 40: Intradermal Syringe - Product Description 25
Table 41: Mega Jet - Product Status 26
Table 42: Mega Jet - Product Description 26
Table 43: Multi-Port Orifices - Product Status 26
Table 44: Multi-Port Orifices - Product Description 26
Table 45: Needle-Free Vaccine Delivery Device - Product Status 27
Table 46: Needle-Free Vaccine Delivery Device - Product Description 27
Table 47: Medical International Technologies (Mit Canada) Inc Pipeline Products & Ongoing Clinical Trials Overview 28
Table 48: MED-JET MBX Injector - Product Status 28
Table 49: MED-JET MBX Injector - Product Description 28
Table 50: MIT-H-III - Product Status 29
Table 51: MIT-H-III - Product Description 29
Table 52: MIT-H-IV-1 - Product Status 29
Table 53: MIT-H-IV-1 - Product Description 29
Table 54: MIT-H-IV-5 - Product Status 30
Table 55: MIT-H-IV-5 - Product Description 30
Table 56: MIT-H-VI Dental Injector - Product Status 30
Table 57: MIT-H-VI Dental Injector - Product Description 30
Table 58: PharmaJet Inc Pipeline Products & Ongoing Clinical Trials Overview 31
Table 59: Tropis - Product Status 31
Table 60: Tropis - Product Description 31
Table 61: Variable Volume Drug Delivery Device - Product Status 32
Table 62: Variable Volume Drug Delivery Device - Product Description 32
Table 63: PharmaJet Inc - Ongoing Clinical Trials Overview 33
Table 64: Tropis - A First in Human Phase I Study of INVAC-1 as a Single Agent in Patients with Advanced Cancer 34
Table 65: Tropis - A Phase II Study of INVAC-1 as Treatment of Patients With High-risk Chronic Lymphocytic Leukemia 34
Table 66: Tropis - A Pragmatic Trial to Quantitatively and Qualitatively Assess Different Techniques for the ID Administration of Fractional Dose IPV in a Campaign Setting in the Gambia 34
Table 67: Tropis - A Randomized, Parallel Design Study to Compare the Safety and Effectiveness of Gardasil When Delivered per Standard Practice (Full Dose, Intramuscular (IM) Delivery Using a Needle and Syringe) Vs. Full Dose, IM Delivery via Needle-free Jet Injection or Reduced Dose, Intradermal Delivery via Needle-free Jet Injection 35
Table 68: Queen's University Pipeline Products & Ongoing Clinical Trials Overview 36
Table 69: Hydrogel-Based Microneedle - Product Status 36
Table 70: Hydrogel-Based Microneedle - Product Description 36
Table 71: Takeda Pharmaceutical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 37
Table 72: Needle-Free Drug Delivery Device - Product Status 37
Table 73: Needle-Free Drug Delivery Device - Product Description 37
Table 74: Teva Pharmaceutical Industries Ltd Pipeline Products & Ongoing Clinical Trials Overview 38
Table 75: MicroDose Needlefree System - Product Status 38
Table 76: MicroDose Needlefree System - Product Description 38
Table 77: Glossary 145
1.2 List of Figures
Figure 1: Needle Free Injections - Pipeline Products by Stage of Development 8
Figure 2: Needle Free Injections - Pipeline Products by Territory 9
Figure 3: Needle Free Injections - Pipeline Products by Regulatory Path 10
Figure 4: Needle Free Injections - Pipeline Products by Estimated Approval Date 11
Figure 5: Needle Free Injections - Ongoing Clinical Trials 12
